Robert Jacks

Robert has 20 years of experience in the biopharmaceutical industry. He has founded or co-founded multiple companies and raised more than $150 million. Previously, Robert was the President & CEO of Indalo Therapeutics, a clinical-stage biotechnology company developing therapeutics for serious fibrotic diseases, and President, CFO, and Co-Founder of Symbiomix Therapeutics, which was sold after achieving NDA approval for Solosec®. Robert also previously held the positions of Head of Corporate Development for Tobira Therapeutics, Head of Business Development for ACT Biotech, and Entrepreneur-in-Residence for OrbiMed Advisors.